Beam Therapeutics Stock
Developer of genome editing technologies.
Sign up today and learn more about Beam Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Beam Therapeutics Stock
Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.
Investors
ARCH Venture Partners
Grail, Prime Medicine, Aledade, Codiak Biosciences, Mindstrong, Metacrine, Beam Therapeutics
Funding History
| April 2018 | $13.0M |
|---|---|
| May 2018 | $74.0M |
Management
Co-Founder
J. Keith Joung
Chief Scientific Officer
Giuseppe Ciaramella
Co-Founder
David R. Liu
Co-Founder and Board Member
Feng Zhang
Chief Executive Officer and Board Member
John Evans
Press
Wall Streets Journal - Mar, 6 2019
Precision-Drug Startup Beam Therapeutics Raises $135 MillionGlobal University Venturing - May, 15 2018
Beam Therapeutics lasers in on $87m series AEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
